Description: atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. atai is headquartered in Berlin, with offices in New York and London.
Home Page: www.atai.life
ATAI Technical Analysis
Krausenstrasse 9-10
Berlin,
10117
Germany
Phone:
49 89 2153 9035
Officers
| Name | Title |
|---|---|
| Mr. Christian Angermayer | Founder & Chairman of the Supervisory Board |
| Mr. Florian Brand | Co-founder & CEO |
| Dr. Srinivas G. Rao M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Rolando Gutierrez-Esteinou M.D. | Chief Medical Officer |
| Mr. Gregory L. Weaver CPA, M.B.A. | Non-Employee Advisor |
| Mr. Stephen B. Bardin | MD & CFO |
| Mr. Frank Stegert | VP of Investment & Venture Management |
| Ms. Anne Johnson | Chief Accounting Officer |
| Ms. Madison Crawford | Sr. Mang. of Accounting |
| Mr. Aaqil Anwar | Mang. of Corp. Fin. & Investor Relations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7768 |
| Price-to-Sales TTM: | 1194.3 |
| IPO Date: | 2021-06-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 87 |